Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy Pharmaceutical Business ReviewThe approval covers both adult and paediatric patients aged eight years and above.Rare DiseaseRead full story pharminent August 20, 2026 (Last updated: August 23, 2026) Pharmaceutical Business Review The approval covers both adult and paediatric patients aged eight years and above. Rare Disease Read full story Post navigation Previous: Moderna and Merck’s Personalized Melanoma Vaccine Scores Historic Phase 3 WinNext: Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026